| Name | Title | Contact Details |
|---|---|---|
Corey Hebert |
Director of Medical Research/Development | Profile |
Yutaka Niihara |
Chief Executive Officer | Profile |
Therapy designed to address an unmet and growing need in the CNS and substance abuse space.
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla`s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is La Jolla`s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is our next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
UCS Healthcare is a healthcare organization offering a variety of services from medical to treatment.
AMGIT is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
CARF-accredited: Largest private nonprofit agency in Santa Clara County providing mental health services to over 3800 youth, adults and older adults annually.